Abstract
Background Anti-tuberculosis drug-induced liver injury (AT-DILI) in tuberculosis (TB) patients has been linked to polymorphisms in genes encoding drug metabolism enzymes and proteins.
Objective This study aimed to monitor polymorphisms of NAT2, PXR, ABCB1, and GSTT1 genes in TB patients from three states (Manipur, Tripura, and Nagaland) in the North Eastern Region of India.
Methods Genomic DNA was isolated from the whole blood samples of TB patients (n=219; Manipur:139; Tripura: 60; Nagaland: 20). The TaqMan allelic discrimination assay and statistical tools were used to investigate single nucleotide polymorphisms (SNP) patterns in NAT2, PXR, ABCB1, and GSTT1 genes.
Results In the study population, ten distinct genotypes of the NAT2 gene and single variation in the PXR, ABCB1, and GSTT1 genes were identified. A strong linkage disequilibrium (LD) was observed between rs1801280 and rs1799931 of the NAT2 gene. Majority of the study populations were intermediate (~46.1%), rest were either slow acetylators (~35.6%) or fast acetylators. Interestingly, ~55% of the TB patients in Tripura were slow acetylators and majority in Manipur and Nagaland were of intermediate acetylator genotypes. For all of the markers investigated, the population had a greater prevalence of ancestral alleles and genotypes. According to a combinational study of the genotypes linked to AT-DILI, ~26.1% of the population possessed the risk genotypes.
Conclusion These TB patients from north eastern states of India were found as carriers of the ancestral alleles and genotypes. And the risk for AT-DILI during TB treatment is low. Expanding such studies with additional markers and larger sample sizes will be useful to generate precise population-specific pharmacogenomics details for efficient TB management.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This project is funded by the Department of Biotechnology, Ministry of Science and Technology, Govt. of India, New Delhi ( BT/PR23238/NER/95/636/2017 dated 19-03-2018).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the ethical committees of Jawaharlal Nehru Institute of Medical Sciences (JNIMS)-Imphal, Manipur (Ref No. Ac/04/IEC/JNIMS/2017), Agartala Govt. Medical College (AGMC)-Agartala, Tripura (Ref. No. F.4(6-9)/AGMC/Academic/IEC Committee/2015/8965 dated 25th April 2018); and Naga Hospital Authority (NHAK)-Kohima, Nagaland (NHAK/HLRC-008/2012 dated 17th May 2017), Manipur University (MU), (Ref No. Ac/IHEC/MU/003/2017) and International Centre for Genetic Engineering and Biotechnology (ICGEB), New Delhi (IEC/IRB No. ICGEB/IEC/2018/06).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data related to the manuscript are available with the authors.
